Biologic

BOSTON — Among caregivers of children with asthma, 54% did not “strongly agree” or “agree” that biologics are safe, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster presented at the CHEST Annual Meeting.

More patients with moderate to severe Crohn’s disease achieved histologic response at week 52 with mirikizumab vs. ustekinumab, regardless of prior biologic exposure, according to data presented at UEG Week.

The CDC has estimated that 58.5 million U.S. adults have arthritis, with the number projected to increase to 78 million by 2040.

The sternoclavicular joint has high native stability, with static stabilization provided by the joint capsule, costoclavicular and interclavicular ligaments.

Published results showed autologous bone marrow aspirate concentrate injections may not provide benefit as an adjuvant for patients with meniscal tears and concomitant knee osteoarthritis who undergo arthroscopic partial meniscectomy.

Patients with severe eosinophilic asthma who used depemokimab administered every 6 months experienced a 54% reduction in exacerbations over 52 weeks, according to a study presented at the European Respiratory Society International Congress.

Patients with greater impairment before initiating biologic treatment for asthma had better response across all assessed outcomes, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

SAN ANTONIO — Patients with urticaria who do not respond to omalizumab have other options for treatment, David A. Khan, MD, said during the 16th Annual Allergy, Asthma & Immunology CME Conference.

Most of us are familiar with the different classes of eye drops.